Heart disease is the leading cause of death for women, and the risk is even higher for those with obesity. In a groundbreaking decision, the U.S. Food and Drug Administration (FDA) has approved Wegovy, a GLP-1 (semaglutide) to help reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease who are overweight or obese.
This approval marks a major advancement for women’s health, offering a new way to protect the heart while addressing weight management. But how do GLP-1s work, and is it right for you? Here’s what you need to know.
GLP-1s were initially developed to manage type 2 diabetes by lowering blood sugar levels and reducing appetite. However, recent studies have revealed that it also offers powerful cardioprotective benefits for people at high risk of heart disease, particularly those with obesity.
Key Benefits:
At Systole Health, we offer personalized virtual care that helps women understand their risk factors, explore treatment options like GLP-1s, and make lifestyle changes that protect their heart. Whether you’re managing weight loss, high blood pressure, or cholesterol, our expert team and supportive community are here to help you take control of your heart health.
Ready to take the next step in protecting your heart? Join one of our virtual group sessions at Systole Health to learn how treatments like GLP-1s and heart-healthy lifestyle changes can help you reduce your cardiovascular risk. Don’t wait for a health scare—start protecting your heart today.